Hostname: page-component-586b7cd67f-t7czq Total loading time: 0 Render date: 2024-11-20T07:18:58.145Z Has data issue: false hasContentIssue false
  • English
  • Français

Costs and outcomes of risperidone treatment in schizophrenia in the Czech Republic

Published online by Cambridge University Press:  16 April 2020

L. Hosák  and
R. Bahbouh
L. Hosák*
Affiliation:
Department of Psychiatry, Charles University, 500 05 Hradec Králové, Czech Republic
R. Bahbouh
Affiliation:
Department of Psychology, Charles University, Prague, Czech Republic
*
Corresponding author. E-mail address: [email protected] (L. Hosák).
Get access

Summary

The increasing cost of pharmaceuticals in the Czech Republic has led to restrictions on the prescription of more expensive atypical antipsychotics. The aim of the study was to compare the costs and outcomes of using risperidone versus classical neuroleptics in treatment of schizophrenia in order to see if there was any cost advantage in restricting use of more recent antipsychotics. Sixty-seven patients (39 women) with a mean age of 34.6 years (S.D. = 9.74) suffering from schizophrenia or schizoaffective disorder were treated with risperidone while 67 patients (39 women) with the same diagnoses with a mean age of 35.7 years (S.D. = 9.91) received standard neuroleptics. Yearly direct medical costs and outcomes (indicated by the average Global Assessment of Functioning score) were assessed retrospectively in an open, intent-to-treat study by abstracting psychiatric outpatient charts. The outcomes were not significantly different between the treatment groups while the risperidone treatment was significantly more expensive than the therapy with standard neuroleptics. This result which appears to be inconsistent with the literature was caused by the cheap labor force in the Czech Republic. The difference between the followed treatments in the direct costs will probably become insignificant in the future when the country’s economy will be more developed.

Keywords

SchizophreniaRisperidoneStandard neurolepticsCostOutcome
Type
Original Articles
Information
European Psychiatry , Volume 17 , Issue 4 , July 2002 , pp. 213 - 221
Copyright
Copyright © Éditions scientifiques et médicales Elsevier SAS 2002

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Aronson, S.MCost-effectiveness and quality of life in psychosis: the pharmacoeconomics of risperidone. Clin Ther 1997; 19; 139–47.CrossRefGoogle ScholarPubMed
Borison, RLPathiraja, APDiamond, BIMeibach, RCRisperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 1992; 28; 213–8.Google Scholar
Chouinard, GKopala, LLabelle, ABeauclair, LJohnson, SVSingh, KIPhase-IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia, The RIS-CAN-3 Study Group. Can J Psychiatry 1998; 43; 1018–25.CrossRefGoogle ScholarPubMed
Česká lékařska komora a Ministerstvo zdravotnictví ČR. Seznam zdravotních výkonů s bodovými hodnotami 1998. 1. vydání 1998. Praha: Strategie, 1998.Google Scholar
Český statistický úřad. Statistická ročenka České republiky. 1. vydání. Praha: Český statistický úřad; 1998.Google Scholar
Davies, AAdena, MAKeks, NACatts, SVLambert, TSchweitzer, IRisperidone versus haloperidol: I. Meta-analysis of efficacy and safety. Clin Ther 1998; 20; 58–71.CrossRefGoogle ScholarPubMed
Davies, LMDrummond, MFEconomics and schizophrenia: the real cost. Br J Psychiatry 1994; 165 (Suppl 25): 18–21.CrossRefGoogle Scholar
Davies, ALangley, PCKeks, NACatts, SVLambert, TSchweitzer, IRisperidone versus haloperidol: II. Cost-effectiveness. Clin Ther 1998; 20; 196–213.CrossRefGoogle ScholarPubMed
De Oliveira, IRMiranda-Scippa, AMDe Sena, EPPereira, ELRibeiro, MGDe Castro-e-Silva, Eet al. Risperidone versus haloperidol in the treatment of schizophrenia: a meta-analysis comparing their efficacy and safety. J Clin Pharm Ther 1996; 21; 349–58.CrossRefGoogle ScholarPubMed
Finley, PRSommer, BRCorbitt, JLBrunson, GHLum, BLRisperidone: clinical outcome predictors and cost-effectiveness in a naturalistic setting. Psychopharmacol Bull 1998; 34; 75–81.Google Scholar
Franěk, J1. Farmakoekonomická konference. Medicína 1998; 5; 1–2.Google Scholar
Gallhofer, BBauer, ULis, SKrieger, SGruppe, HCognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs. Eur Neuropsychopharmacol 1996; 6 (Suppl 2): S13–20.CrossRefGoogle ScholarPubMed
Galvin, PMKnezek, LDRush, AJToprac, MGJohnson, BClinical and economic impact of newer versus older antipsychotic medications in a community mental health center. Clin Ther 1999; 21; 1105–16.CrossRefGoogle Scholar
Green, MFMarshall, BD Jr, Wirshing, WCAmes, DMarder, SRMcGurk, Set al. Does risperidone improve verbal working memory in treatment-resistant schizophrenia. Am J Psychiatry 1997; 154; 799–804.Google ScholarPubMed
Gutierrez-Esteinou, RGrebb, JARisperidone: an analysis of the first 3 years in general use. Int Clin Psychopharmacol 1997; 12 (Suppl 4): S3–S10.CrossRefGoogle ScholarPubMed
Hosák, LFarmakoekonomika v psychiatrii. 1. vydání Praha: Galén; 2000.Google Scholar
Iskedjian, MHux, MRemington, GJThe Canadian Experience with risperidone for the treatment of schizophrenia: an overview. J Psychiatry Neurosci 1998; 23; 229–39.Google ScholarPubMed
Karen, PFilip, VLéčba schizofrenie risperidonem z farmakoekonomického hlediska. 1. vydání Praha: Pharmnet; 1996.Google Scholar
Kee, KSKern, RSMarshall, BD Jr, Green, MFRisperidone versus haloperidol for perception of emotion in treatment-resistant schizophrenia: preliminary findings. Schizophr Res 1998; 31; 159–65.CrossRefGoogle ScholarPubMed
Kern, RSGreen, MFMarshall, BD Jr, Wirshing, WCWirshing, DMcGurk, SRetal.Risperidone versus haloperidol on secondary memory: can newer medications aid learning. Schizophr Bull 1999; 25; 223–32.CrossRefGoogle ScholarPubMed
Knapp, MCosts of schizophrenia. Br J Psychiatry 1997; 171; 509–18.CrossRefGoogle ScholarPubMed
Kubek, MPožadujte vyšší mzdy. Tempus Medicorum 2000; 9: 18.Google Scholar
Marder, SRDavis, JMChouinard, GThe effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997;58:538–46.CrossRefGoogle ScholarPubMed
Möller, HJBäuml, JFerrero, FFuger, JGeretsegger, CKasper, Set al.Risperidone in the treatment of schizophrenia: results of a study of patients from Germany, Austria and Switzerland. Eur Arch Psychiatry Clin Neurosci 1997;247:291–6.CrossRefGoogle ScholarPubMed
Morris, SHogan, TMcGuire, AThe cost-effectiveness of clozapine. A survey of the literature. Clin Drug Invest 1998;15: 137–52.CrossRefGoogle ScholarPubMed
Nightengale, BSCrumly, JMLiao, JLawrence, BJJacobs, EWEconomic outcomes of antipsychotic agents in a Medicaid population: traditional agents vs. risperidone. Psychopharmacol Bull 1998;34:373–82.Google Scholar
Percudani, MFattore, GGalletta, JMita, PTConsinni, AAltamura, ACHealth care cost of therapy-refractory schizophrenic patients treated with clozapine: a study in a community psychiatric services in Italy. Acta Psychiatr Scand 1999;99: 274–80.CrossRefGoogle Scholar
Revicki, DAPharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia. Schizophr Res 1999;35(Suppl):S101– 9.CrossRefGoogle ScholarPubMed
Revicki, DALuce, BRPharmacoeconomic research applied to psychopharmacology development and evaluation. Methods of pharmacoeconomic evaluation of new medical treatments in psychiatry. Psychopharmacol Bull 1995;31:57–65.Google Scholar
Rossi, AMancini, FStratta, PMattei, PGismondi, RPozzi, Fet al.Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study. Acta Psychiatr Scand 1997;95:40–3.CrossRefGoogle Scholar
Schiller, MJShumway, MHargreaves, WATreatment costs and patient outcomes with use of risperidone in a public mental health setting. Psychiatr Serv 1999;50:228–32.CrossRefGoogle Scholar
Směnný, kurz. Hospodářské noviny 1999 1999;43(Suppl (No.1, January 4th, 1999)):S1.Google Scholar
Smith, RCChua, JWLipetsker, BBhattacharyia, AEfficacy of risperidone in reducting positive and negative symptoms in medication-refractory schizophrenia: an open prospective study. J Clin Psychiatry 1996;57:460–6.CrossRefGoogle Scholar
Song, FRisperidone in the treatment of schizophrenia: a metaanalysis of randomized controlled trials. J Psychopharmacol 1997;11:65–71.CrossRefGoogle Scholar
Světová zdravotnická organizace, Mezinárodní klasifikace nem-ocí. 10. revize. Dusevní poruchy a poruchy chování. 1. vydání. Praha: Psychiatrické centrum Praha; 1992.Google Scholar
Skoda, CPapes, ZBaudis, PEis, ZProbstová, VKvantifikace du˚sledku˚ transformace zdravotnictví na poskytování psychiatrické péce v CR. Ekonomické aspekty. 1. vydání. Praha: Psychiatrické centrum Praha; 1998.Google Scholar
Viale, GMechling, LMaislin, GDurkin, MEngelhart, LLawrence, BJImpact of risperidone on the use of mental health care resources. Psychiatr Serv 1997;48:1153–9.Google ScholarPubMed
Všeobecná zdravotní pojist’ovna CR. CíselníkyVZP. 1. vydání. Praha: Vseobecná zdravotní pojistovna CR; 1997.Google Scholar
Wyatt, RJHenter, ILeary, MCAn economic evaluation of schizophrenia 1991. Soc Psychiatry Psychiatr Epidemiol 1995; 30:196–205.Google ScholarPubMed
Ztráta ministerskych nemocnic se prohlubuje. Zdravotnické noviny 2001;20:20.Google Scholar
Submit a response

Comments

No Comments have been published for this article.